

UC San Diego

UC San Diego Previously Published Works

Title

Corrigendum: Pyroptosis and gasdermins-Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis.

Permalink

<https://escholarship.org/uc/item/64t9k62s>

Authors

Stoess, Christian

Leszczynska, Aleksandra

Kui, Lin

et al.

Publication Date

2024

DOI

10.3389/fcell.2024.1461581

Peer reviewed



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Ariel E. Feldstein,
✉ afeldstein@ucsd.edu

RECEIVED 08 July 2024
ACCEPTED 10 July 2024
PUBLISHED 16 October 2024

CITATION
Stoess C, Leszczynska A, Kui L and Feldstein AE (2024), Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis. *Front. Cell Dev. Biol.* 12:1461581. doi: 10.3389/fcell.2024.1461581

COPYRIGHT
© 2024 Stoess, Leszczynska, Kui and Feldstein. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

Christian Stoess^{1,2}, Aleksandra Leszczynska¹, Lin Kui¹ and Ariel E. Feldstein^{1*}

¹Department of Pediatric Gastroenterology, University of California, San Diego, San Diego, CA, United States, ²Department of Surgery, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

KEYWORDS

pyroptosis, gasdermins, liver, steatotic liver disease, steatohepatitis, MASH, MASLD

A Corrigendum on
[Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis](#)

by Stoess C, Leszczynska A, Kui L and Feldstein AE (2023). *Front. Cell Dev. Biol.* 11:1218807. doi: 10.3389/fcell.2023.1218807

In the published article, there was an error in the **Conflict of interest** statement—author, Ariel E. Feldstein was erroneously excluded. The corrected **Conflict of interest** statement appears below.

“Author AEF is an employee and stockholder of Novo Nordisk.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The author apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.